[go: up one dir, main page]

SG11201900744SA - Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them - Google Patents

Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them

Info

Publication number
SG11201900744SA
SG11201900744SA SG11201900744SA SG11201900744SA SG11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA SG 11201900744S A SG11201900744S A SG 11201900744SA
Authority
SG
Singapore
Prior art keywords
international
johnson
rule
methods
superfamily member
Prior art date
Application number
SG11201900744SA
Inventor
Mark Chiu
Di Zhang
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201900744SA publication Critical patent/SG11201900744SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

OX tend 0.9 OX405F2IgG1 0.8 An DX405621661 + protein G beads E 0.6 0.1 33 100 333 1000 Reagent (nghnl) Figure 111. • HEK-Blue. OX40 cells -A- HEK-Blue 0X40 cells +Raji cells 1000 Reagent (nghnl) W O 20 18/03 1400 Al 40 20 10 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 February 2018 (15.02.2018) WIP0 I PCT °mons °nolo III ium VIII iflo oimIE (10) International Publication Number WO 2018/031400 Al (51) International Patent Classification: C07K 16/12 (2006.01) C07K 16/40 (2006.01) CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2017/045466 (22) International Filing Date: 04 August 2017 (04.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/374,347 12 August 2016 (12.08.2016) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). (72) Inventors: CHIU, Mark; 1400 McKean Road, Spring House, Pennsylvania 19044 (US). ZHANG, Di; 1400 McK- ean Road, Spring House, Pennsylvania 19477 (US). (74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: FC ENGINEERED ANTI-TNFR SUPERFAMILY MEMBER ANTIBODIES HAVING ENHANCED AGONISTIC AC- TIVITY AND METHODS OF USING THEM Figure IA (57) : The present invention relates to engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them. [Continued on next page] WO 2018/031400 Al MIDEDIMOMMIDIREIEHEIOMOEMONEMOVOIS Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201900744SA 2016-08-12 2017-08-04 Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them SG11201900744SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374347P 2016-08-12 2016-08-12
PCT/US2017/045466 WO2018031400A1 (en) 2016-08-12 2017-08-04 Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them

Publications (1)

Publication Number Publication Date
SG11201900744SA true SG11201900744SA (en) 2019-02-27

Family

ID=61158615

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900744SA SG11201900744SA (en) 2016-08-12 2017-08-04 Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them

Country Status (11)

Country Link
US (2) US20180044430A1 (en)
EP (1) EP3497126A4 (en)
JP (2) JP7009448B2 (en)
KR (1) KR102554331B1 (en)
CN (1) CN109843916B (en)
AU (2) AU2017308734A1 (en)
CA (1) CA3033665A1 (en)
IL (1) IL264515A (en)
MA (1) MA45941A (en)
SG (1) SG11201900744SA (en)
WO (1) WO2018031400A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885423T3 (en) 2013-02-07 2021-12-13 Massachusetts Gen Hospital Procedures for expansion or depletion of regulatory T cells
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation TYPE II ANTI-RECEPTOR AGONISTIC ANTIBODIES OF TUMOR NECROSIS FACTOR
CN116715767A (en) 2016-05-13 2023-09-08 综合医院公司 Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
JP7577446B2 (en) * 2017-02-10 2024-11-05 ジェンマブ ビー．ブイ． Polypeptide variants and their uses
DK3601358T5 (en) 2017-08-03 2024-09-02 Alector Llc ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEREOF
CA3074317C (en) 2017-08-25 2024-06-18 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
KR20210061350A (en) * 2018-08-20 2021-05-27 더 제너럴 하스피탈 코포레이션 Antagonistic anti-tumor necrosis factor receptor superfamily polypeptide
WO2020061210A1 (en) * 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
RU2734432C1 (en) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds gitr
WO2021063313A1 (en) * 2019-09-30 2021-04-08 深圳市菲鹏生物制药股份有限公司 Fc variant having altered effector function and fusion protein thereof
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
JP7702735B2 (en) * 2021-03-05 2025-07-04 国立研究開発法人農業・食品産業技術総合研究機構 Method, device, and program for generating a prediction model for predicting agricultural crop production performance
CA3216034A1 (en) 2021-04-25 2022-11-03 Xiaofeng Yang Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ES2341666T3 (en) 1991-12-02 2010-06-24 Medimmune Limited PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE.
DK0672142T3 (en) 1992-12-04 2001-06-18 Medical Res Council Multivalent and multi-specific binding proteins as well as their preparation and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001056603A1 (en) 2000-02-01 2001-08-09 Tanox, Inc. Cd40-binding apc-activating molecules
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (en) 2000-11-30 2013-06-04 Medarex, Inc. Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US7550140B2 (en) 2002-06-13 2009-06-23 Crucell Holland B.V. Antibody to the human OX40 receptor
MXPA05012475A (en) 2003-05-23 2006-05-25 Wyeth Corp Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof.
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN101124245A (en) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc-binding proteins, and methods related thereto
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
WO2006104989A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
JP5027804B2 (en) 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド Humanized anti-CD40 antibodies and methods of use thereof
DE102005028778A1 (en) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
CN101952312A (en) 2007-07-31 2011-01-19 米迪缪尼有限公司 Multispecific epitope binding proteins and uses thereof
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
SG186656A1 (en) 2007-12-14 2013-01-30 Bristol Myers Squibb Co Binding molecules to the human ox40 receptor
CN101970730A (en) 2007-12-19 2011-02-09 森托科尔奥索生物科技公司 Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (en) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド Methods for humanizing and affinity maturating antibodies
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102574924A (en) 2009-09-03 2012-07-11 先灵公司 Anti-gitr antibodies
SI2506871T1 (en) 2009-11-30 2016-12-30 Janssen Biotech, Inc. ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
NZ705128A (en) 2010-03-04 2015-04-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012026227A2 (en) 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. human or humanized monoclonal antibody, bispecific molecule, expression vector, transformed cell, composition, and, uses of an antibody
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
AU2011275749C1 (en) 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
EA031849B1 (en) 2010-08-23 2019-03-29 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Anti-ox40 antibodies and methods of using the same
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
RU2604490C2 (en) 2010-11-05 2016-12-10 Займворкс Инк. DESIGN OF STABLE HETERODIMERIC ANTIBODY WITH MUTATIONS IN Fc DOMAIN
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS
CA2845810C (en) 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
EP2773671B1 (en) 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
JP6514103B2 (en) * 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． Dimer protein with triple mutation
KR102270618B1 (en) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 Anti-cd40 antibodies and methods of use
KR20220156667A (en) 2013-01-10 2022-11-25 젠맵 비. 브이 Human igg1 fc region variants and uses thereof
KR102216003B1 (en) 2013-03-15 2021-02-16 얀센 바이오테크 인코포레이티드 Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
MD20180107A2 (en) * 2013-03-18 2019-06-30 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof
MX2015016814A (en) * 2013-06-14 2016-08-08 Bayer Pharma AG Anti-tweakr antibodies and uses thereof.
MA40871A (en) * 2014-10-29 2017-09-05 Novartis Ag DIRECT EXPRESSION OF ANTIBODIES
DK3247728T3 (en) * 2015-01-20 2020-07-13 Igm Biosciences Inc TUMOR CROSS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF
EP3280736A1 (en) * 2015-04-07 2018-02-14 F. Hoffmann-La Roche AG Antigen binding complex having agonistic activity and methods of use
CA3007031A1 (en) 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
KR20250036943A (en) * 2016-08-02 2025-03-14 비스테라, 인크. Engineered polypeptides and uses thereof

Also Published As

Publication number Publication date
CA3033665A1 (en) 2018-02-15
EP3497126A4 (en) 2020-04-08
EP3497126A1 (en) 2019-06-19
KR102554331B1 (en) 2023-07-10
JP2022033769A (en) 2022-03-02
CN109843916B (en) 2023-10-31
US20180044430A1 (en) 2018-02-15
CN109843916A (en) 2019-06-04
US20200231693A1 (en) 2020-07-23
US11359029B2 (en) 2022-06-14
AU2017308734A1 (en) 2019-02-14
KR20190038629A (en) 2019-04-08
AU2024219359A1 (en) 2024-09-26
IL264515A (en) 2019-02-28
WO2018031400A1 (en) 2018-02-15
JP2019532025A (en) 2019-11-07
JP7009448B2 (en) 2022-02-10
MA45941A (en) 2019-06-19

Similar Documents

Publication Publication Date Title
SG11201900744SA (en) Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201908847TA (en) Apparatuses, systems and methods for imaging flow cytometry
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201810687SA (en) Serum albumin-binding fibronectin type iii domains
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging